secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001193125-22-297978
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru reports FY2022 net loss $83.8M; sabizabulin EUA faces FDA advisory panel 8-5 vote against
--------------------------------------------------------------------------------

- Full-year net loss $83.8M ($1.05 diluted EPS) vs net income $7.4M in FY2021.
- Total net revenues fell to $39.4M from $61.3M; FC2 product sales decline cited.
- R&D spending surged to $70.6M from $32.7M on sabizabulin and oncology programs.
- FDA advisory committee voted 8-5 against sabizabulin EUA; final FDA decision pending.
- Cash and equivalents $80.2M at Sept. 30, 2022, down from $122.4M a year earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/0001193125-22-297978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/d384863d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-297978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer